Merck CEO sees human trials for COVID-19 vaccine candidate 'fairly soon'
LONDON, Sept 3- Merck aims to start human trials on one of its COVID-19 vaccine candidates “fairly soon,” with a second vaccine candidate likely to begin trials later this year, Chief Executive Kenneth Frazier said on Thursday. Merck this year bought Austrian vaccine maker Themis Bioscience to gain its vaccine project that relies on a measles vector, and is also…
LONDON, Sept 3 (Reuters) – Merck aims to start human
trials on one of its COVID-19 vaccine candidates “fairly soon,”
with a second vaccine candidate likely to begin trials later
this year, Chief Executive Kenneth Frazier said on Thursday.
Merck this year bought Austrian vaccine maker ThemisBioscience to gain its vaccine project that relies on a measlesvector, and is also collaborating with research nonprofit IAVIon a second vaccine hopeful that uses the same technology asMerck’s Ebola vaccine ERVEBO.
“Both of those are going forward,” Frazier said during avirtual briefing sponsored by drug industry group InternationalFederation of Pharmaceuticals Manufacturers & Association. “Weexpect to be able to start larger-scale human trials in themeasles-virus vaccine fairly soon, and we expect to be able tostart those clinical trials for the (IAVI vaccine) later thisyear.”(Reporting by John MillerEditing by Keith Weir)
ANA NEWS WIRE Disclaimer:
The African News Agency (ANA) is a news wire service and therefore subscribes to the highest standards of journalism as it relates to accuracy, fairness and impartiality.
ANA strives to provide accurate, well sourced and reliable information across Text, Images and Video. Where errors do appear, ANA will seek to correct these timeously and transparently.
The ANA platform also contains news and information from third party sources. ANA has sought to procure reliable content from trusted news sources but cannot be held responsible for the accuracy and opinions provided by such sources on the ANA platform or linked sites.
The content provided for on the ANA News Wire platform, both through the ANA news operation and via its third party sources, are for the sole use of authorised subscribers and partners. Unauthorised access to and usage of ANA content will be subject to legal steps. ANA reserves its rights in this regard.
ANA makes every effort to ensure that the website is up and running smoothly at all times, however ANA does not take responsibility for, and will not be held liable for times when the website is temporarily unavailable due to technical issues that are beyond our control.